AstraZeneca: IMFINZI improved event-free survival, OS across MIBC
Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, administered ...
Is AstraZeneca PLC (AZN) the Best Foreign Dividend Stock to Buy According to Analysts?
We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...
cambridgeindependent1d
AstraZeneca revenues rise to $54bn as it enters ‘unprecedented’ period for company
AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...
AZN Lawsuit Alert! Class Action Against AstraZeneca Plc.
A class action lawsuit was filed against AstraZeneca Plc (AZN) by Levi & Korsinsky on December 23, 2024. The plaintiffs ...
AstraZeneca shares rise as China probe update reassures
AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising ...
FierceBiotech1d
Conduit taps Charles River to build preclinical autoimmune case for AstraZeneca diabetes asset
Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles ...
The inside story of Britain’s failure to clinch £450mn AstraZeneca deal
How an agreement set up by the Tories and lauded by Labour fell victim to cost-cutting and UK curbs on drugs expenditure ...
Zawya5h
Over 67 million screenings – AstraZeneca’s ‘Healthy Heart Africa’ celebrates 10 years of transforming Noncommunicable Disease (NCD) care
AstraZeneca’s ( www.AstraZeneca.com) flagship health equity programme - Healthy Heart Africa (HHA), marks its 10th ...
AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
AstraZeneca's cancer drug tops list of new brands launched in 2024
Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...
Down 13% from its year high at £116.50 now, AstraZeneca’s share price looks cheap to me anywhere under £219.81
AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the ...
Hosted on MSN6h
AstraZeneca offered 'significant' sum, says minister
The government has defended its negotiations with AstraZeneca, after the pharmaceutical giant ditched a planned £450m investment last week, blaming a shortfall in government funding. Science ...